253 related articles for article (PubMed ID: 21987815)
1. Direct activation of antigen-presenting cells is required for CD8+ T-cell priming and tumor vaccination.
Kratky W; Reis e Sousa C; Oxenius A; Spörri R
Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17414-9. PubMed ID: 21987815
[TBL] [Abstract][Full Text] [Related]
2. MyD88/CD40 Genetic Adjuvant Function in Cutaneous Atypical Antigen-Presenting Cells Contributes to DNA Vaccine Immunogenicity.
Collinson-Pautz MR; Slawin KM; Levitt JM; Spencer DM
PLoS One; 2016; 11(10):e0164547. PubMed ID: 27741278
[TBL] [Abstract][Full Text] [Related]
3. A new dynamic model of CD8+ T effector cell responses via CD4+ T helper-antigen-presenting cells.
Xiang J; Huang H; Liu Y
J Immunol; 2005 Jun; 174(12):7497-505. PubMed ID: 15944248
[TBL] [Abstract][Full Text] [Related]
4. A new TLR2 agonist promotes cross-presentation by mouse and human antigen presenting cells.
Santone M; Aprea S; Wu TY; Cooke MP; Mbow ML; Valiante NM; Rush JS; Dougan S; Avalos A; Ploegh H; De Gregorio E; Buonsanti C; D'Oro U
Hum Vaccin Immunother; 2015; 11(8):2038-50. PubMed ID: 26024409
[TBL] [Abstract][Full Text] [Related]
5. Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma.
Goforth R; Salem AK; Zhu X; Miles S; Zhang XQ; Lee JH; Sandler AD
Cancer Immunol Immunother; 2009 Apr; 58(4):517-30. PubMed ID: 18719913
[TBL] [Abstract][Full Text] [Related]
6. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.
Woo SR; Fuertes MB; Corrales L; Spranger S; Furdyna MJ; Leung MY; Duggan R; Wang Y; Barber GN; Fitzgerald KA; Alegre ML; Gajewski TF
Immunity; 2014 Nov; 41(5):830-42. PubMed ID: 25517615
[TBL] [Abstract][Full Text] [Related]
7. Tumor masses support naive T cell infiltration, activation, and differentiation into effectors.
Thompson ED; Enriquez HL; Fu YX; Engelhard VH
J Exp Med; 2010 Aug; 207(8):1791-804. PubMed ID: 20660615
[TBL] [Abstract][Full Text] [Related]
8. Direct T cell activation via CD40 ligand generates high avidity CD8+ T cells capable of breaking immunological tolerance for the control of tumors.
Soong RS; Song L; Trieu J; Lee SY; He L; Tsai YC; Wu TC; Hung CF
PLoS One; 2014; 9(3):e93162. PubMed ID: 24664420
[TBL] [Abstract][Full Text] [Related]
9. Differential requirements of CD4(+) T-cell signals for effector cytotoxic T-lymphocyte (CTL) priming and functional memory CTL development at higher CD8(+) T-cell precursor frequency.
Umeshappa CS; Nanjundappa RH; Xie Y; Freywald A; Xu Q; Xiang J
Immunology; 2013 Apr; 138(4):298-306. PubMed ID: 23113741
[TBL] [Abstract][Full Text] [Related]
10. Cutting edge: CD8+ effector T cells reject tumors by direct antigen recognition but indirect action on host cells.
Schüler T; Blankenstein T
J Immunol; 2003 May; 170(9):4427-31. PubMed ID: 12707316
[TBL] [Abstract][Full Text] [Related]
11. CD8+ T-cell expansion and maintenance after recombinant adenovirus immunization rely upon cooperation between hematopoietic and nonhematopoietic antigen-presenting cells.
Bassett JD; Yang TC; Bernard D; Millar JB; Swift SL; McGray AJ; VanSeggelen H; Boudreau JE; Finn JD; Parsons R; Evelegh C; Damjanovic D; Grinshtein N; Divangahi M; Zhang L; Xing Z; Wan Y; Bramson JL
Blood; 2011 Jan; 117(4):1146-55. PubMed ID: 21088134
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus-enhanced receptor-mediated transferrinfection for the generation of tumor vaccines.
Schweighoffer T; Berger M; Buschle M; Schmidt W; Birnstiel ML
Cytokines Mol Ther; 1996 Sep; 2(3):185-91. PubMed ID: 9384703
[TBL] [Abstract][Full Text] [Related]
13. B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines.
Colluru VT; McNeel DG
Oncotarget; 2016 Oct; 7(42):67901-67918. PubMed ID: 27661128
[TBL] [Abstract][Full Text] [Related]
14. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
van Elsas A; Hurwitz AA; Allison JP
J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
[TBL] [Abstract][Full Text] [Related]
15. Basophils can directly present or cross-present antigen to CD8 lymphocytes and alter CD8 T cell differentiation into IL-10-producing phenotypes.
Kim S; Shen T; Min B
J Immunol; 2009 Sep; 183(5):3033-9. PubMed ID: 19667092
[TBL] [Abstract][Full Text] [Related]
16. Exploiting the role of endogenous lymphoid-resident dendritic cells in the priming of NKT cells and CD8+ T cells to dendritic cell-based vaccines.
Petersen TR; Sika-Paotonu D; Knight DA; Simkins HM; Hermans IF
PLoS One; 2011 Mar; 6(3):e17657. PubMed ID: 21483862
[TBL] [Abstract][Full Text] [Related]
17. CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.
den Boer AT; van Mierlo GJ; Fransen MF; Melief CJ; Offringa R; Toes RE
Cancer Res; 2005 Aug; 65(15):6984-9. PubMed ID: 16061684
[TBL] [Abstract][Full Text] [Related]
18. Deletion of naive CD8 T cells requires persistent antigen and is not programmed by an initial signal from the tolerogenic APC.
Redmond WL; Hernandez J; Sherman LA
J Immunol; 2003 Dec; 171(12):6349-54. PubMed ID: 14662832
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells activated by an anti-inflammatory agent induce CD4(+) T helper type 2 responses without impairing CD8(+) memory and effector cytotoxic T-lymphocyte responses.
Wang Y; Da'Dara AA; Thomas PG; Harn DA
Immunology; 2010 Mar; 129(3):406-17. PubMed ID: 19922421
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
